NL
DE
11 May 2020
In a joined effort led by the Derk ten Berge group of ErasmusMC, the team of Hendrik Marks, theme Cancer development and immune defense, identified an exciting new "rosette" state of pluripotency as reported in Nature Cell Biology. See here for a preview in Nature Cell Biology putting these findings in perspective.
The rosette pluripotent state is characterized by the co-expression of naive factors with the transcription factor OTX2. Downregulation of blastocyst WNT signals drives the transition into rosette pluripotency by inducing OTX2. The rosette then activates MEK signals that induce lumenogenesis and drive further developmental progression. Importantly, the combined WNT and MEK inhibition now supports derivation of in vitro rosette-like stem cells, a self-renewing naive-primed intermediate. Altogether, the rosette is therefore a reversible pluripotent intermediate whereby control over both pluripotency progression and morphogenesis pivots from WNT to MEK signals.
In a joined effort led by the Derk ten Berge group of ErasmusMC, the team of Hendrik Marks, theme Cancer development and immune defense, identified an exciting new "rosette" state of pluripotency as reported in Nature Cell Biology. See here for a preview in Nature Cell Biology putting these findings in perspective.
The rosette pluripotent state is characterized by the co-expression of naive factors with the transcription factor OTX2. Downregulation of blastocyst WNT signals drives the transition into rosette pluripotency by inducing OTX2. The rosette then activates MEK signals that induce lumenogenesis and drive further developmental progression. Importantly, the combined WNT and MEK inhibition now supports derivation of in vitro rosette-like stem cells, a self-renewing naive-primed intermediate. Altogether, the rosette is therefore a reversible pluripotent intermediate whereby control over both pluripotency progression and morphogenesis pivots from WNT to MEK signals.
Related news items
T cell immunity is directed by tetraspanin CD53
5 July 2022 T cells are immune cells that are key for the defense against pathogens and cancer. T cells depend on the membrane protein CD45 to initiate T cell receptor signaling, but how CD45 is controlled at the molecular level is poorly understood. read more
A single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta
21 June 2022 The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription. read more
Dutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs
14 June 2022 The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma. read more
European grants for groundbreaking Radboudumc research Professors Roshan Cools and Peter Friedl receive ERC Advanced Grant
26 April 2022The European Research Council (ERC) is awarding grants to Roshan Cools and Peter Friedl, both professors at Radboudumc. While Cools will investigate how brains control behaviour in (stressful) situations, Friedl will work on developing a new cancer therapy.
read more
Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation published in Cellular and Molecular Life Sciences
20 April 2022 Lisa Huis in ‘t Veld, Nataschja Ho and colleagues from the team of Gosse Adema published in Cellular and Molecular Life Sciences that Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation. read more
